We are live on ! Find out more
MCRB icon

Seres Therapeutics
MCRB

76 hedge funds and large institutions have $820M invested in Seres Therapeutics in 2016 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 36 increasing their positions, 13 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

225% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 4

177% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 13

10% more funds holding

Funds holding: 69 → 76 (+7)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

20% less capital invested

Capital invested by funds: $1.03B → $820M (-$208M)

39% less call options, than puts

Call options by funds: $931K | Put options by funds: $1.52M

Holders
76
Holders Change
+7
Holders Change %
+10.14%
% of All Funds
2.03%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
13
Increased
36
Reduced
13
Closed
4
Calls
$931K
Puts
$1.52M
Net Calls
-$592K
Net Calls Change
-$2.44M

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$10.5M
2
Federated Hermes
Federated Hermes
Pennsylvania
+$8.96M
3
BM
Bridger Management
New York
+$8.61M
4
BA
BlackRock Advisors
Delaware
+$8.07M
5
PCM
Portolan Capital Management
Massachusetts
+$3.11M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$4.33M
2
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$2.91M
3
KCM
Kennedy Capital Management
Missouri
-$507K
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$282K
5
OPPM
Opus Point Partners Management
New York
-$227K
Name Holding Trade Value Shares
Change 		Change in
Stake
State Street
26
State Street
Massachusetts
$3.08M -$6.26K -12 -0.2%
Northern Trust
27
Northern Trust
Illinois
$2.43M +$25.6K +49 +1%
UBS AM
28
UBS AM
Illinois
$2.35M +$40.2K +77 +2%
SM
29
Sabby Management
Florida
$1.84M +$1.53M +2,939 +560%
Goldman Sachs
30
Goldman Sachs
New York
$1.53M +$952K +1,824 +173%
BIM
31
BlackRock Investment Management
Delaware
$1.33M +$13.6K +26 +1%
BlackRock
32
BlackRock
New York
$1.29M +$21.4K +41 +2%
Morgan Stanley
33
Morgan Stanley
New York
$1.22M +$320K +613 +36%
Bank of New York Mellon
34
Bank of New York Mellon
New York
$1.04M +$109K +209 +12%
TD Asset Management
35
TD Asset Management
Ontario, Canada
$855K +$451K +864 +116%
ProShare Advisors
36
ProShare Advisors
Maryland
$796K -$70.5K -135 -8%
TCIM
37
TIAA CREF Investment Management
New York
$670K -$5.74K -11 -0.9%
GC
38
Globeflex Capital
California
$661K +$650K +1,245 New
OPPM
39
Opus Point Partners Management
New York
$645K -$227K -435 -26%
Charles Schwab
40
Charles Schwab
California
$624K +$12K +23 +2%
PPA
41
Parametric Portfolio Associates
Washington
$490K +$482K +923 New
California State Teachers Retirement System (CalSTRS)
42
California State Teachers Retirement System (CalSTRS)
California
$482K +$57.9K +111 +14%
DekaBank Deutsche Girozentrale
43
DekaBank Deutsche Girozentrale
Germany
$422K +$438K +840 New
Swiss National Bank
44
Swiss National Bank
Switzerland
$341K +$83.5K +160 +31%
TA
45
Teachers Advisors
New York
$339K – – –
Citigroup
46
Citigroup
New York
$331K +$116K +222 +55%
CS
47
Credit Suisse
Switzerland
$254K +$25.1K +48 +11%
Millennium Management
48
Millennium Management
New York
$253K -$4.33M -8,299 -95%
Susquehanna International Group
49
Susquehanna International Group
Pennsylvania
$253K +$248K +476 New
New York State Common Retirement Fund
50
New York State Common Retirement Fund
New York
$236K +$54.8K +105 +31%
1
2
3 4

MCRB Hedge Fund Activity: Q1 2016 in Review

76 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q1 2016, worth a combined $820M — down 20% from $1.03B a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new MCRB positions and 4 closed out — a net gain of 9 holders — while 36 added to existing stakes and 13 trimmed.

The largest buyer was Vanguard Group, adding an estimated $10.5M. The largest seller was Millennium Management, cutting an estimated $4.33M.

  • 76 institutional investors held Seres Therapeutics (MCRB) as of Q1 2016, up from 69 in Q4 2015.
  • Funds reported $820M of Seres Therapeutics stock for Q1 2016, down 20% quarter-over-quarter.
  • 13 funds opened new Seres Therapeutics positions in Q1 2016 and 4 closed out, a net change of +9 holders.
  • The largest Seres Therapeutics buyer in Q1 2016 was Vanguard Group, an estimated $10.5M added.
  • The largest Seres Therapeutics seller in Q1 2016 was Millennium Management, an estimated $4.33M sold.

Based on aggregated 13F filings for Q1 2016.